IL296296A - Compounds for treating or inhibiting recurrence of acute myeloid leukemia - Google Patents

Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Info

Publication number
IL296296A
IL296296A IL296296A IL29629622A IL296296A IL 296296 A IL296296 A IL 296296A IL 296296 A IL296296 A IL 296296A IL 29629622 A IL29629622 A IL 29629622A IL 296296 A IL296296 A IL 296296A
Authority
IL
Israel
Prior art keywords
compound
inhibitor
amino
pyrrolo
alkyl
Prior art date
Application number
IL296296A
Other languages
English (en)
Hebrew (he)
Original Assignee
Flash Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flash Therapeutics Llc filed Critical Flash Therapeutics Llc
Publication of IL296296A publication Critical patent/IL296296A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL296296A 2020-03-16 2021-03-15 Compounds for treating or inhibiting recurrence of acute myeloid leukemia IL296296A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/079464 WO2021184154A1 (en) 2020-03-16 2020-03-16 Compounds for treating or inhibiting recurrence of acute myeloid leukemia
PCT/US2021/022322 WO2021188417A1 (en) 2020-03-16 2021-03-15 Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
IL296296A true IL296296A (en) 2022-11-01

Family

ID=77767943

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296296A IL296296A (en) 2020-03-16 2021-03-15 Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Country Status (15)

Country Link
US (1) US11963960B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121430A4 (cg-RX-API-DMAC7.html)
JP (1) JP7744358B2 (cg-RX-API-DMAC7.html)
KR (1) KR102990081B1 (cg-RX-API-DMAC7.html)
CN (1) CN115298180B (cg-RX-API-DMAC7.html)
AR (1) AR121570A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020436612A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018345A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168988A1 (cg-RX-API-DMAC7.html)
IL (1) IL296296A (cg-RX-API-DMAC7.html)
MX (1) MX2022011407A (cg-RX-API-DMAC7.html)
PE (1) PE20230461A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552169A1 (cg-RX-API-DMAC7.html)
TW (1) TWI899184B (cg-RX-API-DMAC7.html)
WO (2) WO2021184154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
AU2021289345A1 (en) * 2020-06-08 2023-01-19 Halia Therapeutics, Inc. Inhibitors of NEK7 kinase
CN114075190A (zh) 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂
CN113861179A (zh) * 2021-10-22 2021-12-31 上海应用技术大学 一种新型flt3激酶抑制剂及其合成与应用
WO2025124429A1 (zh) * 2023-12-11 2025-06-19 北京康辰药业股份有限公司 芳香胺化合物及其药物组合物、应用
WO2025151010A1 (ko) * 2024-01-11 2025-07-17 주식회사 펠레메드 신규한 피롤로트리아진 유도체 및 이의 용도
KR20250157634A (ko) 2024-04-29 2025-11-05 대한민국(질병관리청 국립보건연구원장) Bax 활성제를 유효성분으로 포함하는 항-hiv-1 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808281A (pt) 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
NZ510588A (en) 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2005074603A2 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
US7772231B2 (en) 2005-12-29 2010-08-10 Abbott Laboratories Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
JP6327713B2 (ja) 2012-07-27 2018-05-23 国立研究開発法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
USRE48175E1 (en) * 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US10266535B2 (en) 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
US20190255056A1 (en) 2016-09-15 2019-08-22 Riken A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia
CN118027041A (zh) * 2019-05-31 2024-05-14 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
AU2020301399B2 (en) 2019-06-24 2025-12-18 Dana-Farber Cancer Institute, Inc. HCK degraders and uses thereof
CN114746095B (zh) 2019-10-08 2025-01-24 达纳-法伯癌症研究所有限公司 Hck作为myd88突变疾病的治疗靶点
MX2022008148A (es) * 2020-01-02 2022-07-21 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de btk.
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Also Published As

Publication number Publication date
CN115298180A (zh) 2022-11-04
PH12022552169A1 (en) 2024-01-29
JP2023518035A (ja) 2023-04-27
EP4121430A1 (en) 2023-01-25
CA3168988A1 (en) 2021-09-23
WO2021184154A1 (en) 2021-09-23
AU2021239828A1 (en) 2025-04-03
KR102990081B1 (ko) 2026-07-10
BR112022018345A2 (pt) 2022-11-08
AR121570A1 (es) 2022-06-15
WO2021188417A1 (en) 2021-09-23
US20210299128A1 (en) 2021-09-30
TW202200583A (zh) 2022-01-01
JP7744358B2 (ja) 2025-09-25
AU2020436612A1 (en) 2022-09-01
AU2021239828B2 (en) 2025-06-26
TWI899184B (zh) 2025-10-01
US11963960B2 (en) 2024-04-23
PE20230461A1 (es) 2023-03-14
CN115298180B (zh) 2025-06-10
KR20220154164A (ko) 2022-11-21
MX2022011407A (es) 2022-10-13
EP4121430A4 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
AU2021239828B2 (en) Compounds for treating or inhibiting recurrence of acute myeloid leukemia
JP7721501B2 (ja) Cd38の阻害剤としてのヘテロ二環式アミド
US11198699B2 (en) Compounds targeting PRMT5
IL301524A (en) Tricyclic pyridones and pyrimidones
TWI436769B (zh) 類Polo激酶抑制劑
EP2611802B1 (de) Bicyclische aza-heterocyclen und ihre verwendung
CA3247639A1 (en) CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
EP3079700B1 (en) Soluble guanylate cyclase activators
EP2807159B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent pour le traitement du cancer
TW202334138A (zh) 癌症治療方法
CN102159574A (zh) 三-环吡唑并吡啶激酶抑制剂
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
KR20160146778A (ko) Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
WO2021108483A1 (en) Therapeutic compounds
EA012926B1 (ru) Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
WO2015178955A1 (en) Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
CA2620740A1 (en) Pyridazinone derivatives used for the treatment of pain
EP4413004A1 (en) Macrocyclic compounds having ent1 inhibiting activity
US20230295122A1 (en) 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis
EP3980412A2 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
TW201309703A (zh) 作為蛋白質酪胺酸激酶抑制劑之新穎磺醯胺哌□衍生物及其醫藥用途
WO2023046128A1 (en) A cyclin-dependent kinase inhibitor
HK40083594A (en) Compounds for treating or inhibiting recurrence of acute myeloid leukemia
WO2025252117A1 (zh) 选择性cdk抑制剂化合物及其应用